Annexon Inc
ANNX2.475USD
+0.025+1.02%
交易中 （美東）報價延遲15分鐘
271.54M總市值
虧損本益比TTM
關於 Annexon Inc 公司
Annexon, Inc. 是一家臨牀階段的生物製藥公司。該公司致力於推進針對患有經典補體介導的身體、大腦和眼睛神經炎症疾病患者的後期臨牀治療平臺。該公司利用其平臺識別和描述補體途徑在三個治療領域的作用：自身免疫、神經退行性疾病和眼科。其主要候選藥物 ANX005 是一種研究性單克隆抗體 (mAb)，在關鍵的 III 期臨牀試驗中配製爲靜脈注射，用於治療格林-巴利綜合徵 (GBS) 患者。該公司正在評估 ANX007，一種配製爲玻璃體內注射的抗原結合片段 (Fab)，用於治療地圖狀萎縮 (GA) 患者。該公司正在開發 ANX1502，這是一種用於治療自身免疫適應症的口服小分子。該公司已經開發了 ANX009，一種配製爲皮下給藥的 C1q 阻斷 Fab。
公司簡介
公司代碼ANNX
公司名稱Annexon Inc
上市日期Jul 24, 2020
CEOMr. Douglas E. Love, Esq.
員工數量100
證券類型Ordinary Share
年結日Jul 24
公司地址1400 Sierra Point Parkway
城市BRISBANE
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編94005
電話16508225500
網址https://annexonbio.com/
公司代碼ANNX
上市日期Jul 24, 2020
CEOMr. Douglas E. Love, Esq.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Michael Overdorf
Mr. Michael Overdorf
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
81.75K
-1.03%
Ms. Jennifer Lew
Ms. Jennifer Lew
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
81.33K
-1.35%
Dr. Ted Yednock, Ph.D.
Dr. Ted Yednock, Ph.D.
Executive Vice President, Chief Innovation Officer
Executive Vice President, Chief Innovation Officer
24.66K
-4.33%
Dr. Jamie Dananberg, M.D.
Dr. Jamie Dananberg, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
7.48K
-90.47%
Dr. Dean Rick Artis, Ph.D.
Dr. Dean Rick Artis, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
--
--
Mr. William D. Waddill
Mr. William D. Waddill
Independent Director
Independent Director
--
--
Ms. Jung E. Choi
Ms. Jung E. Choi
Independent Director
Independent Director
--
--
Dr. William H. Carson, M.D.
Dr. William H. Carson, M.D.
Independent Director
Independent Director
--
--
Mr. Muneer A. Satter, J.D.
Mr. Muneer A. Satter, J.D.
Independent Director
Independent Director
--
--
Mr. William (Bj) Jones, Jr.
Mr. William (Bj) Jones, Jr.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Michael Overdorf
Mr. Michael Overdorf
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
81.75K
-1.03%
Ms. Jennifer Lew
Ms. Jennifer Lew
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
81.33K
-1.35%
Dr. Ted Yednock, Ph.D.
Dr. Ted Yednock, Ph.D.
Executive Vice President, Chief Innovation Officer
Executive Vice President, Chief Innovation Officer
24.66K
-4.33%
Dr. Jamie Dananberg, M.D.
Dr. Jamie Dananberg, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
7.48K
-90.47%
Dr. Dean Rick Artis, Ph.D.
Dr. Dean Rick Artis, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
--
--
Mr. William D. Waddill
Mr. William D. Waddill
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
12.09%
BlackRock Institutional Trust Company, N.A.
6.94%
Alerce Investment Management, L.P.
6.75%
BVF Partners L.P.
6.38%
Logos Global Management LP
6.02%
Other
61.82%
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
12.09%
BlackRock Institutional Trust Company, N.A.
6.94%
Alerce Investment Management, L.P.
6.75%
BVF Partners L.P.
6.38%
Logos Global Management LP
6.02%
Other
61.82%
股東類型
持股股東
佔比
Investment Advisor
46.58%
Investment Advisor/Hedge Fund
22.00%
Hedge Fund
18.07%
Private Equity
6.75%
Venture Capital
6.07%
Research Firm
2.33%
Bank and Trust
0.73%
Individual Investor
0.57%
Endowment Fund
0.44%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
324
113.85M
103.77%
-22.18M
2025Q1
339
111.61M
101.75%
-29.54M
2024Q4
329
116.73M
106.58%
-17.05M
2024Q3
303
113.54M
107.51%
-18.37M
2024Q2
291
110.25M
106.60%
-6.79M
2024Q1
286
95.95M
106.04%
-7.64M
2023Q4
274
81.06M
103.56%
+7.91M
2023Q3
277
55.43M
104.79%
-23.79M
2023Q2
273
56.90M
107.89%
-13.92M
2023Q1
276
56.74M
113.00%
-7.66M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Fidelity Management & Research Company LLC
13.26M
12.09%
-961.15K
-6.76%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.62M
6.94%
+55.22K
+0.73%
Mar 31, 2025
Alerce Investment Management, L.P.
7.41M
6.75%
--
--
Mar 31, 2025
BVF Partners L.P.
7.00M
6.38%
--
--
Mar 31, 2025
Logos Global Management LP
6.60M
6.02%
+2.60M
+65.00%
Apr 21, 2025
Redmile Group, LLC
6.30M
5.74%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
5.36M
4.89%
-167.26K
-3.02%
Mar 31, 2025
Bain Capital Life Sciences Investors, LLC
5.25M
4.78%
--
--
Mar 31, 2025
Bellevue Asset Management AG
5.16M
4.7%
--
--
Mar 31, 2025
Sio Capital Management, LLC
3.40M
3.1%
+1.03M
+43.55%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
0.8%
iShares Neuroscience and Healthcare ETF
0.56%
ALPS Medical Breakthroughs ETF
0.18%
iShares Micro-Cap ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
Avantis US Small Cap Equity ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
iShares Biotechnology ETF
0.02%
ProShares Hedge Replication ETF
0.01%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.8%
iShares Neuroscience and Healthcare ETF
佔比0.56%
ALPS Medical Breakthroughs ETF
佔比0.18%
iShares Micro-Cap ETF
佔比0.05%
ProShares Ultra Nasdaq Biotechnology
佔比0.03%
Invesco Nasdaq Biotechnology ETF
佔比0.03%
Avantis US Small Cap Equity ETF
佔比0.03%
iShares Russell 2000 Value ETF
佔比0.02%
iShares Biotechnology ETF
佔比0.02%
ProShares Hedge Replication ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
